Sopharma AD adjusts share prices after capital increase decision

Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director Sopharma AD
Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director - Sopharma AD
0Comments

Sofia, Bulgaria, July 10, 2025 – Sopharma AD has announced an adjustment in the stock exchange price of its shares following a decision to increase capital with its own funds. This corporate event impacts the market price as of July 10, 2025. The adjustment follows decisions made at the Regular General Meeting of Shareholders on June 27, 2025.

The Bulgarian Stock Exchange adjusted the closing price of Sopharma’s shares. On July 9, 2025, the last recorded share price was BGN 7.08. After the adjustment on July 10, 2025, reflecting the theoretical impact of this corporate event, the reference price is now BGN 2.36.

Once the capital increase is registered with both the Commercial Register and Financial Supervision Commission’s register, new shares will be allocated to eligible shareholders’ accounts at Central Depository AD.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.